How long a patient can live with intrapulmonary metastasis from lung cancer needs to be further evaluated based on the patient’s cytologic classification. If the patient has intrapulmonary metastasis from squamous carcinoma, the survival period is about 1 year despite the administration of chemotherapy or other comprehensive treatments such as bioimmunotherapy. If intrapulmonary metastasis belongs to the category of lung adenocarcinoma and genetic testing indicates sensitive gene mutation, gene targeted drug treatment can better prolong the survival of patients, which can reach 2 years or even longer, and there are cases of 8 years survival. Therefore, the intrapulmonary metastasis of lung cancer cannot be determined by one word, and the patient’s survival is also determined by the patient’s cytological classification and the involvement of gene-targeted drugs or not. Without the involvement of gene-targeted drugs, the survival of patients is usually around 1 year. Therefore, the survival and prognosis of a patient is determined based on chest imaging suggestive of intrapulmonary metastasis and then on whether the patient has mutations of gene-targeting drugs.